Omega-3 as an adjunctive therapy of sertraline and venlafaxine substantially improves symptoms of major depressive disorder: A double-blind, placebo-controlled study

Current Psychopharmacology Pub Date : 2021-07-12 DOI:10.2174/2211556010666210712185437

Mohammad Ahadifard Moghaddam, Malihe Farid, M. M. Natanzi, Z. Khodaii, Rahim Badrfam, Atefeh Zandifar

{"title":"Omega-3 as an adjunctive therapy of sertraline and venlafaxine substantially improves symptoms of major depressive disorder: A double-blind, placebo-controlled study","authors":"Mohammad Ahadifard Moghaddam, Malihe Farid, M. M. Natanzi, Z. Khodaii, Rahim Badrfam, Atefeh Zandifar","doi":"10.2174/2211556010666210712185437","DOIUrl":null,"url":null,"abstract":"\n\nDue to the possible effect of omega-3 fatty acids on reducing depressive symptoms, in this study, we investigated these effects in combination with other antidepressants. \n\n\n\nThe study was a double-blind clinical trial on 100 patients with major depressive disorder who were divided into four groups of 25 each and treated with 50 mg daily sertraline plus placebo, 50 mg daily sertraline plus two grams Omega 3 daily, 75 mg daily venlafaxine plus placebo, and 75 mg daily venlafaxine plus 2 g Omega 3 daily for 6 weeks. \n\n\n\nThe mean Hamilton depression rating score of sertraline and venlafaxine plus omega-3 after treatment were 4.42 and 4.23 respectively versus sertraline and venlafaxine plus placebo 14.4 and 14.2 respectively (P value=0.0001). \n\n\n\nOmega-3 enhanced the clinical function of sertraline and venlafaxine to reduce the severity of depression. Adding omega-3 to either sertraline or venlafaxine does not have a comparative advantage over each other in terms of the improvement of severity of depressive symptoms. \n\n\n\nnumber is IRCT20190302042885N1. \n","PeriodicalId":10751,"journal":{"name":"Current Psychopharmacology","volume":"10 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Psychopharmacology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/2211556010666210712185437","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 1

Abstract

Due to the possible effect of omega-3 fatty acids on reducing depressive symptoms, in this study, we investigated these effects in combination with other antidepressants. The study was a double-blind clinical trial on 100 patients with major depressive disorder who were divided into four groups of 25 each and treated with 50 mg daily sertraline plus placebo, 50 mg daily sertraline plus two grams Omega 3 daily, 75 mg daily venlafaxine plus placebo, and 75 mg daily venlafaxine plus 2 g Omega 3 daily for 6 weeks. The mean Hamilton depression rating score of sertraline and venlafaxine plus omega-3 after treatment were 4.42 and 4.23 respectively versus sertraline and venlafaxine plus placebo 14.4 and 14.2 respectively (P value=0.0001). Omega-3 enhanced the clinical function of sertraline and venlafaxine to reduce the severity of depression. Adding omega-3 to either sertraline or venlafaxine does not have a comparative advantage over each other in terms of the improvement of severity of depressive symptoms. number is IRCT20190302042885N1.

查看原文本刊更多论文

Omega-3作为舍曲林和文拉法辛的辅助疗法，可显著改善重度抑郁症的症状:一项双盲、安慰剂对照研究

由于omega-3脂肪酸可能对减轻抑郁症状有作用，在本研究中，我们研究了与其他抗抑郁药联合使用时的效果。该研究是一项对100名重度抑郁症患者进行的双盲临床试验，他们被分为四组，每组25人，接受每日50毫克舍曲林加安慰剂、每日50毫克舍曲林加2克欧米茄3、每日75毫克文拉法辛加安慰剂、每日75毫克文拉法辛加2克欧米茄3的治疗，持续6周。治疗后舍曲林、文拉法辛加omega-3组汉密尔顿抑郁评分均值分别为4.42和4.23，而舍曲林、文拉法辛加安慰剂组汉密尔顿抑郁评分均值分别为14.4和14.2 (P值=0.0001)。Omega-3增强了舍曲林和文拉法辛的临床功能，减轻抑郁症的严重程度。在舍曲林或文拉法辛中加入omega-3在改善抑郁症状的严重程度方面并没有相对优势。号码为IRCT20190302042885N1。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Psychopharmacology

自引率

0.00%

发文量